Core Viewpoint - A new type of injectable nanobody derived from llama antibodies has been developed, offering a potential new treatment avenue for schizophrenia with fewer side effects [1] Summary by Sections Research Findings - The new nanobody specifically activates glutamate receptors, which are key receptors in the brain associated with schizophrenia, potentially improving cognitive impairments that current treatments do not adequately address [1] - The efficacy of the nanobody has been validated in two animal models, showing significant improvement in cognitive abilities of mice with cognitive impairments, with effects lasting over a week post-injection [1] Administration and Safety - The nanobody can be administered via peripheral injection methods such as intravenous or intramuscular routes, and it is biodegradable with minimal side effects [1] Future Directions - Clinical studies are needed to confirm the effectiveness of this treatment approach, and similar therapies may be applicable to other neurological disorders [1]